Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells

Molecular Pharmacology

Volumn 52, Issue 1, 1997, Pages 82-87

  Valenti, Monica ^a,c   Nieves Neira, Wilberto ^a   Kohlhagen, Glenda ^a   Kohn, Kurt W ^a   Wall, Monroe E ^b   Wani, Mansukh C ^b   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; COLON CARCINOMA; CYTOTOXICITY; DNA REPLICATION; DNA TRANSCRIPTION; ENZYME ACTIVATION; ENZYME ACTIVITY; MAMMAL; NONHUMAN; PRIORITY JOURNAL;

EID: 0030756223     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.1.82     Document Type: Article

References (39)

1. Wall, M. E., and M. C. Wani. Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 55:753-760 (1995).
2. Pommier, Y. Eukaryotic DNA topoisomerase I: genome gate keeper and its intruders, camptothecins. Semin. Oncol. 23:1-10 (1996).
3. Chen, A. Y., and L. F. Liu. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 94:194-218 (1994).
4. Gupta, M., A. Fujimori, and Y. Pommier. Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta 1262:1-14 (1995).
5. Wang, J. DNA topoisomerases. Annu. Rev. Biochem. 65:635-692 (1996).
6. Pommier, Y., G. Kohlhagen, F. Kohn, F. Leteurtre, M. C. Wani, and M. E. Wall. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc. Natl. Acad. Sci. USA 92:8861-8865 (1995).
7. O'Connor, P. M., D. Kerrigan, R. Bertrand, K. W. Kohn, and Y. Pommier. 10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in Human colon carcinoma (HT-29) cells. Cancer Commun. 2:395-400 (1990).
8. Tanizawa, A., K. W. Kohn, G. Kohlhagen, F. Leteurtre, and Y. Pommier. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 43:7200-7206 (1995).
9. Luzzio, M. J., J. M. Besterman, D. L. Emerson, M. G. Evans, K. Lackey, P. L. Leitner, G. McIntyre, B. Morton, P. L. Myers, M. Peel, J. M. Sisco, D. D. Sternbach, W.-Q. Tong, A. Truesdale, D. E. Uehling, A. Vuong, and J. Yates. Synthesis and antitumor activity of novel water-soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J. Med. Chem. 38:395-401 (1995).
10. Sawada, S., K. Nokata, T. Fureta, T. Yokokura, and T. Miyasaka. Chemical modification of an antitumor alkaloid, camptothecin. Synthesis and antitumor activity of 7-C-substituted camptothecins. Chem. Pharm. Bull. (Tokyo) 39:2574-80 (1991).
11. Bertrand, R., and Y. Pommier. Assessment of DNA damage in mammalian cells by DNA filtration methods, in Cell Growth and Apoptosis: A Practical Approach (G. Studzinski, ed.). IRL Press, Oxford, 96-117 (1995).
12. Kohn, K. W., R. A. G. Ewig, L. C. Erickson, and L. A. Zwelling. Measurement of strand breaks and crosslinks by alkaline elution, in DNA Repair: A Laboratory Manual of Research Procedures (E. C. Friedberg and P. C. Hanawalt, eds.). Marcel Dekker, New York, 379-401 (1981).
13. Kohn, K. W. DNA filter elution: a window on DNA damage in mammalian cells. Bioessays 18:505-13 (1996).
14. Covey, J. M., C. Jaxel, K. W. Kohn, and Y. Pommier. Protein-linked DNA strand breaks induced in Mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res. 49:5016-5022 (1989).
15. Lackey, K., D. Sternbach, D. Croom, D. Emerson, M. Evans, P. Leitner, M. Luzzio, G. McIntyre, A. Vuong, J. Yates, and J. Besterman. Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin. J. Med. Chem. 39:713-719 (1996).
16. Goldwasser, F., T. Shimizu, P. O'Connor, K. W. Kohn, and Y. Pommier. G2 checkpoint deficiencies are critical determinants for sensitivity to camptothecin. Proc. Am. Assoc. Res. 36:452 (1995).
17. Goldwasser, F., T. Shimizu, J. Jackman, Y. Hoki, P. M. O'Connor, K. W. Kohn, and Y. Pommier. Correlations between S- and G2-phase arrest and cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 56:4430-4437 (1996).
18. Goldwasser, F., I. Bae, A. J. J. Fornace, and Y. Pommier. Differential GADD45, p21CIP1/WAF1, MCL-1, and Topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. Oncol. Res. 7/8:317-323 (1996).
19. Holm, C., J. M. Covey, D. Kerrigan, and Y. Pommier. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49:6365-6368 (1989).
20. Hsiang, Y.-H., L. F. Liu, M. E. Wall, M. C. Wani, A. W. Nicholas, G. Manikumar, S. Kirschenbaum, R. Silber, and M. Potmesil. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res. 49:4385-4389 (1989).
21. O'Connor, P. M., W. Nieves-Neira, D. Kerrigan, R. Bertrand, J. Goldman, K. W. Kohn, and Y. Pommier. S-Phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxy-camptothecin in human colon carcinoma HT-29 cells. Cancer Commun. 3:233-240 (1991).
22. Jaxel, C., K. W. Kohn, M. C. Wani, M. E. Wall, and Y. Pommier. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res. 49:1465-1469 (1989).
23. Hsiang, Y. H., R. Hertzberg, S. Hecht, and L. F. Liu. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:14873-14878 (1985).
24. Hsiang, Y.-H., M. G. Lihou, and L. F. Liu. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077-5082 (1989).
25. Morris, E. J., and H. M. Geller. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J. Cell Biol. 134:757-770 (1996).
26. Pommier, Y., M. Fesen, and F. Goldwasser. DNA topoisomerase II inhibitors: the epipopodophyllotoxins, m-AMSA, and the ellipticine derivatives, in Cancer Chemotherapy: Principles and Practice, 2nd Ed. (B. A. Chabner and D. Longo, eds.). J. B. Lippincott, Philadelphia (1995).
27. Yamashita, Y., Y. Saitoh, K. Ando, K. Takahashi, H. Ohno, and H. Nakano. Saintopin, a new antitumor antibiotic with topoisomerase iI dependent DNA cleavage activity, from Paecilomyces. J. Antibiot. (Tokyo) 43: 1344-1346 (1990).
28. Leteurtre, F., A. Fujimori, A. Tanizawa, A. Chhabra, A. Mazumder, G. Kohlhagen, H. Nakano, and Y. Pommier. Saintopin, a dual inhibitor of DNA topoisomerases I and II, as a probe for drug-enzyme interactions. J. Biol. Chem. 269:28702-28707 (1994).
29. Wassermann, K., J. Markovits, C. Jaxel, G. Capranico, K. W. Kohn, and Y. Pommier. Effects of morpholinyl doxonibicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol. Pharmacol. 38:38-45 (1990).
30. Trask, D. K., and M. T. Muller. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc. Natl. Acad. Sci. USA 85:1417-1421 (1988).
31. Poddevin, B., J.-F. Riou, F. Lavelle, and Y. Pommier. Dual topoisomerase I and II inhibition by intoplicine (RP-60475) a new antitumor agent in early clinical trials. Mol. Pharmacol. 44:767-774 (1993).
32. Kawada, S.-Z., Y. Yamashita, Y. Uosaki, K. Gomi, T. Iwasaki, T. Takiguchi, and H. Nakano. UCT48, a new antitumor antibiotic with topoisomerase II mediated DNA cleavage activity from Streptomyces sp. J. Antibiot. (Tokyo) 45:1182-1184 (1992).
33. Yamashita, Y., N. Fujii, C. Murakata, T. Ashizawa, M. Okabe, and H. Nakano. Induction of mammalian DNA topoisomerase I-mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 31: 12069-12075 (1992).
34. Janin, Y. L., A. Croisy, J.-F. Riou, and E. Bisagni. Synthesis and evaluation of new 6-amino-substituted benzo[c]phenanthridine derivatives. J. Med. Chem. 36:3686-3692 (1993).
35. Wang, L.-K., R. K. Johnson, and S. M. Hecht. Inhibition of topoisomerase I function by nitidine and fagaronine. Chem. Res. Toxicol. 6:813-818 (1993).
36. Nguyen, C. H., E. Fan, J. F. Riou, M. C. Bissery, P. Vrignaud, F. Lavelle, and E. Bisagni. Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-β] and pyrido[3,4-β]quinoxalines: a new class of antineoplastic agents. Anticancer Drug Des. 10:277-297 (1995).
37. Chen, A. Y., C. Yu, A. Bodley, L. F. Peng, and L. F. Liu. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res. 53:1332-1337 (1993).
38. Kim, J. S., Q. Sun, B. Gatto, C. Yu, A. Liu, L. F. Liu, and E. J. La Voie. Structure-activity relationships of benzimidazoles and related heterocycles as topoisomerase I poisons. Bioorg. Med. Chem. 4:621-630 (1996).
39. Sun, Q., B. Gatto, C. Yu, A. Liu, L. F. Liu, and E. J. LaVoie. Synthesis and evaluation of terbenzimidazoles as topoisomerase I inhibitors. J. Med. Chem. 38:3638-3644 (1996).